HTB

Hepatitis coinfection

NICE approves pegylated interferon plus ribavirin in UK

London study finds sexual and intranasal transmission of HCV

HCV-coinfection is associated with diabetes and CD4 decline

Hepatitis coinfection: incidence in Europe and response to transplant

UK guidelines for treating coinfection with HIV and hepatitis B or C published online

Kidney and liver transplantation in HIV-infected patients: case presentations and review

London epidemic of sexually transmitted hepatitis C

Coinfected patients may require longer HCV treatment, irrespective of genotype

Time on anti-HIV therapy is a protective factor for liver fibrosis in HIV-HCV coinfected patients

HIV-HCV co-infected patients have poorer response to HCV therapy

HIV coinfection, reinfection and superinfection

Hepatitis A vaccine provides affordable protection in HIV-positive individuals

PEG-interferon alfa-2b plus ribavirin for treatment of CHC patients who failed or relapsed following interferon-based therapy

Pegylated interferon plus ribavirin improves fibrosis in non-responders to standard interferon therapy

Coinfection: Hepatitis coverage from the Digestive Disease Week Conference

Genotype, enzyme levels, and viral load are clues to hepatitis C virus outcomes

Adherence and mental side effects during HCV treatment with interferon alfa and ribavirin in psychiatric risk groups

Key to hepatitis C virus persistence found

Co-infection: liver transplantation in HIV-positive persons

BHIVA HIV/hepatitis B and HIV/hepatitis C co-infection guidelines (2003): posted to web for consultation

Index of biochemical markers could reduce need for biopsy by half in HIV/HCV co-infected patients

HCV protects against abnormal blood lipids in HAART-treated HIV patients

HCV levels in semen

Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected patients

12-week response predicts which HIV-HCV coinfected patients will not benefit from continued pegylated interferon plus ribavirin

Pegylated interferon associated with eye disorders

European approval of adefovir for hepatitis B

Hepatitis C virus viraemia in HIV-positive individuals with negative HCV antibody tests

Roche’s Copegus (ribaviran) available in UK for use in the treatment of Hepatitis C

PEG-Intron plus ribavirin in non-responders and relapsers

Dangers of HIV/hepatitis B coinfection

The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates

Low dose pegylated interferon is ineffective in treating HIV/HCV co-infected patients

Daily injection more effective than thrice-weekly interferon alpha-2b for HCV/HIV

Early treatment with interferon alpha-2b can prevent chronic liver disease in those with hepatitis C

Harmless hepatitis-type virus seems to extend lives of HIV-positive individuals

Adefovir dipivoxil promising for lamivudine-resistant HBV in HIV-1 infected patients

Severe hepatic injury common after HAART initiation

HCV coinfection may have role in changes in body composition in HIV patients

HIV/HCV coinfection: amid swirling controversy the profile of a killer emerges

French study finds low death rate due to hepatitis C virus in HIV-positive patients

Solid organ transplant in HIV/hepatitis co-infected patients

HIV protease inhibitors associated with hepatic cytolysis

Lamivudine withdrawal may reactivate HBV in HIV-positive patients

Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial

Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients

Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART

Opportunistic illness and viral hepatitis co-infection

Post navigation